In vitro partition of docetaxel and gemcitabine in human volunteer blood: the influence of concentration and gender

被引:11
作者
Dumez, H
Guetens, G
De Boeck, G
Highley, MS
de Bruijn, EA
van Oosterom, AT
Maes, RAA
机构
[1] UZ Gasthuisberg, Dept Clin Oncol, Expt Oncol Lab, B-3000 Louvain, Belgium
[2] Univ Utrecht, Fac Pharmaceut Sci, Utrecht, Netherlands
关键词
docetaxel; erythrocyte; gemcitabine; partition ratio; plasma; red blood cell;
D O I
10.1097/01.cad.0000175585.24317.ca
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We have performed in vitro incubations of blood from male and female volunteers with gemcitabine and docetaxel alone, and in combination, at different concentration gradients in order to investigate changes in partition between red blood cells (RBCs), total plasma and the free fraction. After extraction and sample pre-treatment, a validated high-performance liquid chromatography method followed by UV detection was used to determine the concentrations of both drugs in the different blood constituents. The partition ratio [the concentration in the erythrocytes divided by the concentration in plasma (E/P)] was calculated. The partition ratio of docetaxel varied from 0.02 to 1.44 (mean 0.35), reflecting its relatively low affinity for RBCs, probably because of its high plasma protein binding (more than 98%). For gemcitabine, the partition ratio varied from 1 to 5, reflecting a high affinity for RBCs (less than 10% plasma protein bound). The partition ratios of both drugs increased significantly with higher whole-blood concentrations, favoring uptake in the erythrocytes when plasma protein binding is saturated. Combination incubations showed a complex and unexplained interaction between gender and the influence of docetaxel on the partition of gemcitabine. We conclude that the incorporation of drugs into the RBC pool may be important for transportation to tumor tissue and efficacy. In combination, one anti-cancer agent can alter the partition ratios of other anti-cancer agents.
引用
收藏
页码:885 / 891
页数:7
相关论文
共 14 条
[1]   Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer [J].
Bruno, R ;
Hille, D ;
Riva, A ;
Vivier, N ;
Huinnink, WWTB ;
van Oosterom, AT ;
Kaye, SB ;
Verweij, J ;
Fossella, FV ;
Valero, V ;
Rigas, JR ;
Seidman, AD ;
Chevallier, B ;
Fumoleau, P ;
Burris, HA ;
Ravclin, PM ;
Sheiner, LB .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (01) :187-196
[2]   DESCRIPTION OF AN INSTRUMENT FOR SEPARATION OF RED-CELLS FROM PLASMA AND MEASUREMENT OF RED-CELL VOLUME [J].
DRIESSEN, O ;
HIGHLEY, MS ;
HARPER, PG ;
MAES, RAA ;
DEBRUIJN, EA .
CLINICAL BIOCHEMISTRY, 1994, 27 (03) :195-196
[3]   Human red blood cells: Rheological aspects, uptake, and release of cytotoxic drugs [J].
Dumez, H ;
Reinhart, WH ;
Guetens, G ;
de Bruijn, EA .
CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES, 2004, 41 (02) :159-188
[4]   The impact of drug administration sequence and pharmacokinetic interaction in a phase I study of the combination of docetaxel and gemcitabine in patients with advanced solid tumors [J].
Dumez, H ;
Louwerens, M ;
Pawinsky, A ;
Planting, AST ;
de Jonge, MJA ;
Van Oosterom, AT ;
Highley, M ;
Guetens, G ;
Mantel, M ;
De Boeck, G ;
de Bruijn, E ;
Verweij, J .
ANTI-CANCER DRUGS, 2002, 13 (06) :583-593
[5]  
EXTRA JM, 1993, CANCER RES, V53, P1037
[6]   Erythrocytes and the transport of drugs and endogenous compounds [J].
Highley, MS ;
DeBruijn, EA .
PHARMACEUTICAL RESEARCH, 1996, 13 (02) :186-195
[7]  
Hinderling PH, 1997, PHARMACOL REV, V49, P279
[9]  
KURATA D, 1974, CLIN PHARMACOL THER, V16, P355
[10]   Sensitive determination of docetaxel in human plasma by liquid-liquid extraction and reversed-phase high-performance liquid chromatography [J].
Loos, WJ ;
Verweij, J ;
Nooter, K ;
Stoter, G ;
Sparreboom, A .
JOURNAL OF CHROMATOGRAPHY B, 1997, 693 (02) :437-441